NR3C2 and hydrops fetalis: With regard to the use of disease modifying HF drugs, at 12 months after initial HF diagnosis, 72% of patients were taking beta blockers, 67% renin-angiotensin system inhibitors (11% sacubitril-valsartan), 19% mineralocorticoid receptor antagonists and 10% SGLT2i (74%, 72.5% -12.0%-, 19%, and 9% among patients with HFrEF, respectively).